Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

24.44

-0.18 (-0.73%)

At close: Jan 28, 2026, 4:00 PM EST

24.41

-0.03 (-0.12%)

Pre-market: Jan 29, 2026, 6:50 AM EST

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2015 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2015 - 2020
North America Revenue	361.23M	340.46M	Log In	Log In	Log In	Upgrade
Latin America Revenue	149.78M	130.71M	Log In	Log In	Log In	Upgrade
Europe Revenue	103.38M	80.12M	Log In	Log In	Log In	Upgrade
Asia-Pacific Revenue	16.21M	8.93M	Log In	Log In	Log In	Upgrade
Revenue (Total)	630.60M	560.23M	Log In	Log In	Log In	Upgrade

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2015 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2015 - 2020
Crysvita Revenue	159.23M	134.71M	Log In	Log In	Log In	Upgrade
Dojolvi Revenue	95.59M	88.19M	Log In	Log In	Log In	Upgrade
Evkeeza Revenue	52.70M	32.16M	Log In	Log In	Log In	Upgrade
Mepsevii Revenue	31.67M	30.35M	Log In	Log In	Log In	Upgrade
Total Product Revenue	339.19M	285.42M	Log In	Log In	Log In	Upgrade
Crysvita Royalty Revenue	291.41M	274.82M	Log In	Log In	Log In	Upgrade
Crysvita Collaboration Revenue in Profit-Share Territory	-	-	Log In	Log In	Log In	Upgrade
Crysvita Royalty Revenue in European Territory	-	-	Log In	Log In	Log In	Upgrade
Daiichi Sankyo Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Collaboration and License Revenue	-	-	Log In	Log In	Log In	Upgrade
Revenue (Other)	-52.70M	-32.16M	Log In	Log In	Log In	Upgrade
Revenue (Total)	630.60M	560.23M	Log In	Log In	Log In	Upgrade

Updated Nov 4, 2025. Data Source: Fiscal.ai.